Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/221187
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLázaro, J.-
dc.contributor.authorAlcon, Clara-
dc.contributor.authorLissat, A.-
dc.contributor.authorMontero, J.-
dc.contributor.authorEckert, C.-
dc.date.accessioned2025-05-23T12:58:55Z-
dc.date.available2025-05-23T12:58:55Z-
dc.date.issued2024-05-10-
dc.identifier.issn0300-8630-
dc.identifier.urihttps://hdl.handle.net/2445/221187-
dc.description.abstractResistance to blinatumomab (CD19-CD3 BiTE) is a significant obstacle in the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), prompting the investigation of novel drug combinations. We aimed to generate an "in vitro" model capable of identifying synergistic combinations to enhance blinatumomab's efficacy in BCP-ALL treatment. Drug response profiling used annexin V/propidium iodide/CD3 staining and flow cytometry analysis in 28 patient samples and 4 cell lines. Co-cultured with healthy donor T-cells, samples were treated for 24h with blinatumomab and/or other inhibitors. Differential sensitivity to blinatumomab was observed among patient samples and cell lines. Idelalisib (tyrosin kinase inhibitor; TKi) combined with blinatumomab exhibited potential antagonistic effects. Birinapant (SMAC mimetic) and venetoclax (BCL2 inhibitor) demonstrated increased efficacy in BCP-ALL cell lines, displaying synergistic potential with blinatumomab. Our findings support TKi and SMAC mimetics' immunomodulatory effects, in accordance to prior anti-CD19 CAR T cell reports. Venetoclax emerges as a promising candidate for combination therapy against blinatumomab resistance.-
dc.format.extent2 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherGeorg Thieme Verlag-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1055/s-0044-1786596-
dc.relation.ispartofKlinische Pädiatrie, 2024, vol. 236, num.3-
dc.relation.urihttps://doi.org/10.1055/s-0044-1786596-
dc.rights(c) Georg Thieme Verlag, 2024-
dc.sourceArticles publicats en revistes (Biomedicina)-
dc.subject.classificationLeucèmia-
dc.subject.classificationLeucèmia limfocítica crònica-
dc.subject.classificationMedicaments-
dc.subject.otherLeukemia-
dc.subject.otherChronic lymphocytic leukemia-
dc.subject.otherDrugs-
dc.titleExploring Synergistic Approaches to Enhance Blinatumomab's Efficacy in Acute Lymphoblastic Leukemia-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec750714-
dc.date.updated2025-05-23T12:58:55Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Biomedicina)

Files in This Item:
File Description SizeFormat 
867680.pdf375.98 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.